Shield Therapeutics notes UK launch of Feraccru® by Norgine

5 Dec 2018

Shield Therapeutics plc is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults. In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories. For full details please see the press release below:

Shield Therapeutics Press Release

To view the announcement released by Norgine, please click here.



Back to news

London, UK

16 Upper Woburn Place
London, WC1H 0AF

t+44 (0) 207 186 8500

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau

t+41 (0) 435 080 781

Munich, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin

t+44 (0) 207 186 8500